| Business Summary | | UroMed
Corporation
specializes
in
interventional
urological
products,
with
primary
emphasis
on
the
treatment
of
prostate
cancer.
The
Company
seeks
to
market
a
portfolio
of
products,
including
its
two
main
proprietary
products
for
the
treatment
of
prostate
cancer,
the
CaverMap
Surgical
Aid,
available
to
aid
physicians
in
preserving
vital
nerves
during
prostate
cancer
surgery,
and
the
Symmetra
Iodine-125
(Symmetra
I-125)
radioactive
seeds,
used
in
a
brachytherapy
procedure
to
treat
localized
prostate
cancer.
The
Company's
product
portfolio
also
includes
brachytherapy
introducer
needles.
The
Company
also
continues
to
dedicate
resources
to
the
development
and/or
acquisition
of
product
lines
that
fit
into
its
strategic
platform. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | UroMed
Corporation
is
a
provider
of
urological
products,
with
a
primary
emphasis
on
prostate
cancer.
The
Company
also
has
developed
and
acquired
technology
in
urinary
incontinence
products
and
in
breast
cancer
detection.
For
the
six
months
ended
6/30/01,
revenues
rose
12%
to
$2.5
million.
Net
loss
before
extraordinary
item
rose
71%
to
$3.7
million.
Results
reflect
higher
software
systems
and
support
revenues,
offset
by
increased
personnel
and
amortization
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Simon, 38 Chairman | $225K | $9.3K | Daniel Muscatello, 45 Pres,
Director, CEO | 292K | 11.4K | Paul Pagano, 49 VP
of Domestic Sales | 122K | -- | Domenic Micale, 36 VP
of Fin. and Admin., Treasurer | 118K | 46.6K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|